Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation

Launched by BARTS & THE LONDON NHS TRUST · Jun 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two types of heart valve problems—mitral regurgitation and tricuspid regurgitation—in patients who have a condition called atrial fibrillation, which affects the heart's rhythm. The goal of the study is to better understand how these valve issues develop and to identify factors that could predict their outcomes. Participants will undergo several tests, including heart ultrasounds (echocardiograms) and blood tests, to assess their heart function at the beginning of the study and again after one year.

To be eligible for this trial, participants must be at least 18 years old and have atrial fibrillation along with moderate or severe issues with their heart valves. They should also be able to provide informed consent. However, people with severe left heart problems or certain types of valve disease that are not related to atrial fibrillation will not be included. Overall, this study aims to gather important information that could help improve treatment for individuals with these heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed consent
• • Age of 18 years or older
• • Atrial fibrillation
• • Moderate or severe atrial valve disease
• • Adequate 2D echocardiography views including parasternal long axis, short axis, apical two chamber, apical three chamber and four chamber.
• Exclusion Criteria:
• • Unwilling or unable to give consent
• • Left ventricular impairment (ejection fraction \< 50%).
• • Primary/organic valve disease